at Benzinga.com (Jan 13, 2015)
Sequenom (SQNM -2.3%) goes into the close a bit stronger than it started out the day, recovering...
Sequenom (SQNM -2.3%) goes into the close a bit stronger than it started out the day, recovering some of its earlier 6% dip on some upbeat preliminary FY12 guidance posted over the weekend. The company said that it is expecting revenues of $89M, equating to a Y/Y growth rate of 59%, but the results were largely overshadowed by Illumina's (ILMN -7.3%) acquisition of Verinata, whose competing verifi test - which analyzes fetal DNA naturally found in a pregnant women's blood to look for missing or extra copies of chromosomes - carry's less risk than Sequenom’s SEQureDx technology.
From other sites
at Zacks.com (Dec 4, 2014)
at Zacks.com (Dec 3, 2014)
at CNBC.com (Dec 3, 2014)
at CNBC.com (Jan 14, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs